Real‐world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis
APMIS · 2024
DOI: 10.1111/apm.13453 ↗Kurz gefasst
Fachartikel in der Zeitschrift APMIS, 2024. Verfasst von Thomas Bryrup und 15 weiteren Autor:innen. Beteiligte Einrichtung: The Danish Cystic Fibrosis Cohort, Copenhagen, Aarhus, Denmark. Hauptthemen laut MEDLINE: Cystic Fibrosis, Sweat, Chlorides, Benzodioxoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Sweat chloride concentration, a diagnostic feature in cystic fibrosis (CF), reflects CF transmembrane conductance regulator (CFTR) activity. CFTR modulator therapies, especially elexacaftor/tezacaftor/ivacaftor (ETI), has improved CF outcomes. We report nationwide, real‐world data on sweat chloride concentration in people with CF (pwCF) with and without modulator therapies. All Danish pwCF with a minimum of one F508del allele were included. Sweat chloride measurements were stratified by genotype and modulator treatment. Differences were assessed using mixed‐effects models. We included 977 sweat chloride measurements from 430 pwCF, 71% of which were F508del homozygous. Heterozygous and homozygous ETI‐treated pwCF had an estimated mean sweat chloride concentration of 43 mmol/L (95% confidence interval: 39; 48) and 43 mmol/L (39; 47), respectively—48% and 59% lower than those without treatment. High variation in concentrations remained regardless of treatment status. Despite ETI treatment, 27% heterozygous and 23% homozygous pwCF had elevated concentrations (≥60 mmol/L). These real‐world data confirm a substantial decrease in sweat chloride concentration during modulator treatment, especially ETI, where mean concentrations halved. However, large variation remained, including persistently high concentrations. These findings emphasize the potential of sweat chloride concentration as a treatment response biomarker and the need to explore its heterogeneity and relationship with clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Danish Cystic Fibrosis Cohort, Copenhagen, Aarhus, Denmark.
- Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.
- Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
- Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
- Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Thomas Bryrup, Christian Leo-Hansen, Tavs Qvist
Zitieren
APA
Bryrup, T., Faurholt-Jepsen, D., Pressler, T., Henriksen, E. H., Leo-Hansen, C., Nielsen, B. U., Højte, C., Mathiesen, I. H. M., Katzenstein, T. L., Jeppesen, M., Jensen-Fangel, S., Olesen, H. V., Skov, M., Qvist, T., Olsen, M. F., & TransformCF Study Group (2024). Real‐world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis. APMIS. https://doi.org/10.1111/apm.13453
Vancouver
Bryrup T, Faurholt-Jepsen D, Pressler T, Henriksen EH, Leo-Hansen C, Nielsen BU, et al. Real‐world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis. APMIS. 2024. doi:10.1111/apm.13453
BibTeX
@article{Bryrup2024,
author = {Bryrup, Thomas and Faurholt-Jepsen, Daniel and Pressler, Tacjana and Henriksen, Esben Herborg and Leo-Hansen, Christian and Nielsen, Bibi Uhre and Højte, Christine and Mathiesen, Inger Hee Mabuza and Katzenstein, Terese L and Jeppesen, Majbritt and Jensen-Fangel, Søren and Olesen, Hanne Vebert and Skov, Marianne and Qvist, Tavs and Olsen, Mette Frahm and TransformCF Study Group, TransformCF Study Group},
title = {Real‐world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis},
journal = {APMIS},
year = {2024},
doi = {10.1111/apm.13453}
}
EUVIMED